Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3233-3239

  Navas, E ^a   Salleras, L ^b,c   Dominguez A ^a,b   Ibanez D ^a   Prat, A ^b,c   Sentis J ^b   Garrido, P ^b  

^a GENERALITAT DE CATALUNYA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Cost; Cost benefit analysis; Cost effectiveness analysis; Economic evaluation; Inactivated virosomal subunit influenza vaccine; Provider perspective; Societal perspective

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE;

AGE DISTRIBUTION; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; INFLUENZA; MEDICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIETY; SOCIOECONOMICS;

EID: 33947733297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.038     Document Type: Article

References (14)

1. Salleras L., Dominguez A., Pumarola T., Prat A., Marcos M.A., Garrido P., et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 24 (2006) 6638-6642
2. CDC Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(RR-10):1-42.
3. Haddix A.C., Teutsch S.M., Shaffer P.A., and Duñet D.O. Prevention effectiveness: a guide to decision analysis and economic evaluation (1996), Oxford University Press, New York p. 12-26
4. New Vaccine Surveillance Network. The underrecognized burden of influenza in young children. N Engl J Med 355 (2006) 31-40
5. Bhat N., Wright J.G., Broder K.R., Murkay E.L., Greenberg M.E., Glober M.J., et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 353 (2005) 2559-2567
6. Esposito S., Marchisio P., Cavagna R., Gironi S., Bosis S., Lambertini L., et al. Effectiveness of influenza paediatric vaccination with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine 21 (2003) 3162-3168
7. Hurwitz E.S., Haber M., Chang A., Shope T., Teo S., Ginsberg M., et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 284 (2000) 1677-1682
8. Colombo C., Argiolas L., La Vecchia C., Negri E., Meloni G., and Meloni T. Influenza vaccine in healthy preschool children. Rev Epidemiol Sante Publique 49 (2001) 157-162
9. Principi N., Esposito S., Marchisio P., Gasparini R., and Crovari P. Socioeconomic impact of influenza in healthy children and their families. Pediatr Infect Dis J 22 Suppl. 10 (2003) S207-S210
10. Cohen G.M., and Nettleman M.D. Economic impact of influenza vaccination in preschool children. Paediatrics 106 (2000) 973-976
11. White T., Lavoie S., and Nettleman M.D. Potential cost savings attributable to influenza vaccination of school-aged children. Paediatrics 103 (1999) e73
12. Salo H., Kilpi T., Sintonen H., Linna M., Peltola V., and Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 24 (2006) 4934-4941
13. Meltzer M.I., Neuzil K.M., Griffin M.R., and Fukuda K. An economic analysis of annual influenza paediatric vaccination. Vaccine 23 (2005) 1004-1014
14. Esposito S., Marchisio P., Bosis S., Lambertini L., Claut L., Faelli N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 24 (2006) 629-635